Novel tetracyclic tetrahydrofuran derivatives
AssigneeJanssen Pharmaceutica NV
InventorsJose Cid-Nunez, Antonius Adrianus Megens, Andres Trabanco-Suarez
Life of this patent
Estimating the term…
Loading patent…
AssigneeJanssen Pharmaceutica NV
InventorsJose Cid-Nunez, Antonius Adrianus Megens, Andres Trabanco-Suarez
Estimating the term…
This invention concerns novel substituted unsaturated tetracyclic tetrahydrofuran derivatives with binding affinities towards serotonine receptors, in particular 5-HT2A and 5-HT2C receptors, and towards dopamine receptors, in particular dopamine D2 receptors and with norepinephrine reuptake inhibition properties, pharmaceutical compositions comprising the compounds according to the invention, the use thereof as a medicine, in particular for the prevention and/or treatment of a range of psychiatric and neurological disorders, in particular certain psychotic, cardiovascular and gastrokinetic disorders and processes for their production. The compounds according to the invention can be represented by general Formula (I) and comprises also the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the N-oxide form thereof and prodrugs thereof, wherein all substitutents are defined as in Claim 1.
A compound of Formula (I)
(canceled)
An intermediate compound according to Formula (II) wherein R9, i, j, ring A, ring B and X all have the meaning as described above for a final compound of Formula (I) and W is a suitable leaving group, preferably a halo, alkyl- or arylsulphonyloxy-, in particular 4-(methylphenyl)sulphonyloxy- or iodo.
An intermediate compound according to Formula (VII) wherein R9, i, j, ring A, ring B and X all have the meaning as described above for a final compound of Formula (I).
An intermediate compound according to Formula (VIII) wherein R9, i, j, ring A, ring B and X all have the meaning as described above for a final compound of Formula (I).
Dependencies are inferred from the claim text.